Nature Medicine：首次人体实验，PD-1单抗治疗艾滋病

Core Viewpoint - The article discusses the potential of Budigalimab, an anti-PD-1 monoclonal antibody developed by AbbVie, as a treatment for HIV infection, highlighting its safety and efficacy in a Phase 1b clinical trial, which may lead to a paradigm shift in HIV treatment by enabling "ART-free" control of the virus [2][3][8]. Group 1: Background on HIV and Current Treatments - Approximately 40 million people worldwide are infected with HIV, making it a significant public health threat [2]. - Antiretroviral therapy (ART) is the standard treatment that suppresses HIV replication but does not cure the infection, requiring daily medication which poses adherence challenges [2]. Group 2: Budigalimab Clinical Trial Overview - Budigalimab is a humanized anti-PD-1 monoclonal antibody designed to reverse immune exhaustion in chronic HIV-1 infection [6]. - The Phase 1b clinical trial involved 41 HIV-infected participants, assessing safety, tolerability, and pharmacokinetics through multiple low-dose intravenous injections [6][7]. Group 3: Trial Results and Efficacy - The trial demonstrated good tolerability of Budigalimab, with 29 out of 41 participants experiencing adverse events, mostly mild and unrelated to the treatment [7]. - In a 12-week exploratory efficacy analysis, 6 out of 11 participants showed delayed HIV viral rebound after treatment interruption, indicating potential for sustained viral control without ART [7][8]. Group 4: Implications for Future Research - The successful outcomes of the Phase 1b trial support further Phase 2 clinical trials, aiming to explore the feasibility of "ART-free" HIV control through immune modulation [8].